TGAN.RGT Rights Subscription

Non-transferable rights CUSIP 893RGT027, were distributed to holders of record as of 06/26/23, at the rate of one right for each share of TRANSPHORM INC. common stock (CUSIP 89386L100).  

One (1) right entitles the holder to subscribe for 0.07655623 shares of TRANSPHORM INC. common stock (CUSIP 89386L100), at a subscription price of $3.30 per whole share.

The deadline to submit instructions for exercise will be 2023-07-17 16:00 (HONG KONG GMT+8).

The terms of the offer are as follows:

Option 1: Take no action [Default option]

Option 2: Exercise rights, subscribe for 0.07655623 shares at the estimated subscription price of $3.30 per share

No fractional shares of common stock will be issued and will be rounded up to the nearest whole number.

Not supporting oversubscribed rights issue.

Rights exercised are irrevocable.

Unexercised rights at the end of the offering period are deemed null and void.

There is no guarantee of delivery (protect) privilege afforded to the rights offer.

Please fill in the following information and use the registered email address of Futu to send an email to cs@futuhk.com.

1. Account Number –
2. Name - (In Chinese or English)
3. Stock code – TGAN.RGT
4. Options: (1) [Default option] or (2) 
5. Number of shares participating in corporate actions –

Note to applicants:
1. If shareholders holding less than 1 shares of TGAN.RGT,
they cannot participate in related corporate actions.
2. Option 1 is the default option. We will help clients to choose option 1 if have not received clients’ emails.
3. Once the relevant application is submitted, the stocks participating in the company's actions cannot be traded and the application cannot be withdrawn.
4. This corporate action does not accept additional applications, the maximum number of applications that a client can apply for does not exceed the number of eligible shares it holds.
5. The pending orders and unsettled shares will not be accepted for the time being.
6. Please confirm that the account funds are sufficient to pay the relevant fees of this corporate action. Otherwise, we will not bear any responsibility for the failure of your application.
7. If there is any update, all the information released by the listed company shall prevail.